Restellini Sophie, Afif Waqqas
Division of Gastroenterology, McGill University Health Centre, Montreal, QC H3G 1A4, Canada.
Division of Gastroenterology and Hepatology, Geneva's University Hospitals and University of Geneva, 1205 Geneva, Switzerland.
J Clin Med. 2021 Mar 17;10(6):1242. doi: 10.3390/jcm10061242.
The goal of therapeutic drug monitoring (TDM) is to optimize anti-TNF (tumor necrosis factor) biologic treatment in patients with inflammatory bowel disease (IBD). Although commercial assays are readily available for both ustekinumab and vedolizumab, the use of TDM with these newer biologic medications is at its infancy. The clinical utility of TDM with non-anti-TNF mechanisms of action is not clear. This review summarizes the latest available data on the pharmacokinetics of newer biologic and oral small molecules and highlights the threshold concentrations that have been associated with improved outcomes in IBD patients.
治疗药物监测（TDM）的目标是优化炎症性肠病（IBD）患者的抗TNF（肿瘤坏死因子）生物治疗。尽管乌司奴单抗和维多珠单抗都有现成的商业检测方法，但对这些新型生物药物使用TDM仍处于起步阶段。TDM在非抗TNF作用机制方面的临床实用性尚不清楚。本综述总结了关于新型生物制剂和口服小分子药物药代动力学的最新可用数据，并强调了与IBD患者改善预后相关的阈值浓度。
